A closed automatic modular cell culture system for personalised autologous cell therapy

Recent advances in cell therapy and immunotherapy are changing the face of modern medicine. In particular a new type of treatment – CAR-T therapy – made from the patient’s own immune cells is offering new hope to cancer sufferers. The drawback of these treatments is that they are extraordinarily expensive to produce using current methods and hence are unaffordable to public healthcare systems. The aim of this project is to develop a new type of manufacturing system that dramatically reduces production costs through the use of automation and modular design. By developing and commercialising this technology the project partners ambition is help make CAR-T therapy accessible to everyone and to become world leaders in equipment for cell-therapy manufacturing and in cell-therapy manufacturing services. **** Lead in Jiangsu Province: Aokai (Suzhou) Biomedcial Ltd. Application Reference: SBZ2017000276 ****